Abstract: The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.
Type:
Application
Filed:
February 18, 2011
Publication date:
September 1, 2011
Applicants:
Satoris, Inc., The Board of Trustees of the Leland Stanford Junior University, The U.S. Government represented by the Department of Veterans Affairs
Abstract: The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.
Type:
Grant
Filed:
November 19, 2004
Date of Patent:
October 6, 2009
Assignees:
Satoris, Inc., The Borad of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Department of Veterans Affairs